Risk factors for prostate-specific antigen persistence in pT3aN0 prostate cancer after robot-assisted laparoscopic radical prostatectomy: a retrospective study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The aim of this study was to evaluate the risk factors for prostate-specific antigen (PSA) persistence in pathological stage T3aN0 prostate cancer (PCa) after robot-assisted laparoscopic radical prostatectomy (RALP). Methods: A retrospective study was performed on 326 patients with pT3aN0 PCa who underwent RALP between March 2020 and February 2022. PSA persistence was defined as nadir PSA of >0.1 ng/mL after RALP, and the risk factors for PSA persistence were evaluated using logistic regression analysis. Results: Among 326 patients, 61 (18.71%) had PSA persistence and 265 (81.29%) had PSA of <0.1 ng/mL after RALP (successful radical prostatectomy [RP] group). In the PSA persistence group, 51 patients (83.61%) received adjuvant treatment. Biochemical recurrence occurred in 27 patients (10.19%) in the successful RP group during the mean follow-up period of 15.22 months. Multivariate analysis showed that the risk factors for PSA persistence were large prostate volume (hazard ratio [HR], 1.017; 95% confidence interval [CI], 1.002–1.036; p=0.046), lymphovascular invasion (LVI) (HR, 2.605; 95% CI, 1.022–6.643; p=0.045), and surgical margin involvement (HR, 2.220; 95% CI, 1.110–4.438; p=0.024). Conclusion: Adjuvant treatment may be needed for improved prognosis in patients with pT3aN0 PCa after RALP with a large prostate size, LVI, or surgical margin involvement.
Abstract
Background: The aim of this study was to evaluate the risk factors for prostate-specific antigen (PSA) persistence in pathological stage T3aN0 prostate cancer (PCa) after robot-assisted laparoscopic radical prostatectomy (RALP). Methods: A retrospective study was performed on 326 patients with pT3aN0 PCa who underwent RALP between March 2020 and February 2022. PSA persistence was defined as nadir PSA of >0.1 ng/mL after RALP, and the risk factors for PSA persistence were evaluated using logistic regression analysis. Results: Among 326 patients, 61 (18.71%) had PSA persistence and 265 (81.29%) had PSA of <0.1 ng/mL after RALP (successful radical prostatectomy [RP] group). In the PSA persistence group, 51 patients (83.61%) received adjuvant treatment. Biochemical recurrence occurred in 27 patients (10.19%) in the successful RP group during the mean follow-up period of 15.22 months. Multivariate analysis showed that the risk factors for PSA persistence were large prostate volume (hazard ratio [HR], 1.017; 95% confidence interval [CI], 1.002–1.036; p=0.046), lymphovascular invasion (LVI) (HR, 2.605; 95% CI, 1.022–6.643; p=0.045), and surgical margin involvement (HR, 2.220; 95% CI, 1.110–4.438; p=0.024). Conclusion: Adjuvant treatment may be needed for improved prognosis in patients with pT3aN0 PCa after RALP with a large prostate size, LVI, or surgical margin involvement.
참고문헌 (26)
- Arnas Rakauskas, "Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study", Investigative and Clinical Urology, 62(4), pp.416~422 (2021), 대한비뇨의학회[DOI]
- Klotz L, "Active surveillance in intermediate-risk prostate cancer", BJU Int, 125, pp.346~354 (2020)
- Siegel RL, "Cancer statistics, 2020", CA Cancer J Clin, 70, pp.7~30 (2020)
- Mottet N, "EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1 : Screening, diagnosis, and local treatment with curative intent", Eur Urol, 71, pp.618~629 (2017)
- Jang TL, "Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer", Cancer, 124, pp.4010~4022 (2018)
- van den Ouden D, "Progression in and survival of patients with locally advanced prostate cancer(T3)treated with radical prostatectomy as monotherapy", J Urol, 160, pp.1392~1397 (1998)
- Gözen AS, "Impact of laparoscopic radical prostatectomy on clinical T3 prostate cancer : experience of a single centre with long-term follow-up", BJU Int, 116, pp.102~108 (2015)
- 구교철, "Cancer-Specific Mortality among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-center Study Using Propensity Scoring and Competing Risk Regression Analyses", Cancer Research and Treatment, 50(1), pp.129~137 (2018), 대한암학회
- Moris L, "Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer : an international multidisciplinary systematic review", Eur Urol, 77, pp.614~627 (2020)
- Kliment J Jr, "The long-term outcomes of radical prostatectomy for very high-risk prostate cancer pT3b-T4 N0-1 on definitive histopathology", Cent European J Urol, 70, pp.13~19 (2017)
- Casey JT, "Outcomes of locally advanced(T3 or greater)prostate cancer in men undergoing robot-assisted laparoscopic prostatectomy", J Endourol, 23, pp.1519~1522 (2009)
- Hajili T, "Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation : results of a single-institution series with long-term follow-up", BJU Int, 123, pp.58~64 (2019)
- Shipley WU, "Radiation with or without antiandrogen therapy in recurrent prostate cancer", N Engl J Med, 376, pp.417~428 (2017)
- Wiegel T, "Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival : 10-year data of the ARO 96-02 trial", Int J Radiat Oncol Biol Phys, 91, pp.288~294 (2015)
- Rogers CG, "Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy", Cancer, 101, pp.2549~2556 (2004)
- Moreira DM, "Natural history of persistently elevated prostate specific antigen after radical prostatectomy : results from the SEARCH database", J Urol, 182, pp.2250~2255 (2009)
- Gandaglia G, "Impact of postoperative radiotherapy in men with persistently elevated prostate-specific antigen after radical prostatectomy for prostate cancer : a long-term survival analysis", Eur Urol, 72, pp.910~917 (2017)
- Fossati N, "Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy", Eur Urol, 73, pp.436~444 (2018)
- Preisser F, "Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes", Eur Urol, 76, pp.106~114 (2019)
- Freedland SJ, "Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy : a search database study", J Clin Oncol, 23, pp.7546~7554 (2005)
- 민선호, "Impact of Prostate Size on Pathologic Outcomes and Prognosis after Radical Prostatectomy", Investigative and Clinical Urology, 53(7), pp.463~466 (2012), 대한비뇨의학회[DOI]
- Loeb S, "Lymphovascular invasion in radical prostatectomy specimens : prediction of adverse pathologic features and biochemical progression", Urology, 68, pp.99~103 (2006)
- May M, "Prognostic impact of lymphovascular invasion in radical prostatectomy specimens", BJU Int, 99, pp.539~544 (2007)
- Jamil M, "Impact of lymphovascular invasion on overall survival in patients with prostate cancer following radical prostatectomy : stage-per-stage analysis", Clin Genitourin Cancer, 19, pp.e319~25 (2021)
- Zhang L, "Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy : a meta-analysis from high-quality retrospective cohort studies", World J Surg Oncol, 16, pp.124~ (2018)
- Hegemann NS, "Risk of biochemical recurrence and timing of radiotherapy in pT3a N0 prostate cancer with positive surgical margin : a single center experience", Strahlenther Onkol, 192, pp.440~448 (2016)